BIIB
Price
$131.51
Change
-$1.08 (-0.81%)
Updated
Jul 25, 04:59 PM (EDT)
Capitalization
31.34B
6 days until earnings call
SNY
Price
$50.37
Change
+$0.24 (+0.48%)
Updated
Jul 25, 04:59 PM (EDT)
Capitalization
122.61B
6 days until earnings call
Interact to see
Advertisement

BIIB vs SNY

Header iconBIIB vs SNY Comparison
Open Charts BIIB vs SNYBanner chart's image
Biogen
Price$131.51
Change-$1.08 (-0.81%)
Volume$10.54K
Capitalization31.34B
Sanofi ADS
Price$50.37
Change+$0.24 (+0.48%)
Volume$45.85K
Capitalization122.61B
BIIB vs SNY Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. SNY commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongBuy and SNY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (BIIB: $132.59 vs. SNY: $50.13)
Brand notoriety: BIIB: Notable vs. SNY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 94% vs. SNY: 73%
Market capitalization -- BIIB: $31.34B vs. SNY: $122.61B
BIIB [@Pharmaceuticals: Major] is valued at $31.34B. SNY’s [@Pharmaceuticals: Major] market capitalization is $122.61B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • SNY’s FA Score: 1 green, 4 red.
According to our system of comparison, SNY is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 5 TA indicator(s) are bullish while SNY’s TA Score has 4 bullish TA indicator(s).

  • BIIB’s TA Score: 5 bullish, 4 bearish.
  • SNY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SNY is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +3.03% price change this week, while SNY (@Pharmaceuticals: Major) price change was +3.04% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.04%. For the same industry, the average monthly price growth was +7.04%, and the average quarterly price growth was +12.64%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

SNY is expected to report earnings on Oct 24, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+3.04% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNY($123B) has a higher market cap than BIIB($31.3B). BIIB has higher P/E ratio than SNY: BIIB (26.95) vs SNY (20.80). SNY YTD gains are higher at: 8.546 vs. BIIB (-13.295). SNY has higher annual earnings (EBITDA): 12.6B vs. BIIB (2.04B). SNY has more cash in the bank: 8.98B vs. BIIB (1.05B). BIIB has less debt than SNY: BIIB (7.34B) vs SNY (18.4B). SNY has higher revenues than BIIB: SNY (46.4B) vs BIIB (9.84B).
BIIBSNYBIIB / SNY
Capitalization31.3B123B25%
EBITDA2.04B12.6B16%
Gain YTD-13.2958.546-156%
P/E Ratio26.9520.80130%
Revenue9.84B46.4B21%
Total Cash1.05B8.98B12%
Total Debt7.34B18.4B40%
FUNDAMENTALS RATINGS
BIIB vs SNY: Fundamental Ratings
BIIB
SNY
OUTLOOK RATING
1..100
6873
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
8
Undervalued
PROFIT vs RISK RATING
1..100
10063
SMR RATING
1..100
7175
PRICE GROWTH RATING
1..100
6157
P/E GROWTH RATING
1..100
9689
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SNY's Valuation (8) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (87) in the Biotechnology industry. This means that SNY’s stock grew significantly faster than BIIB’s over the last 12 months.

SNY's Profit vs Risk Rating (63) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (100) in the Biotechnology industry. This means that SNY’s stock grew somewhat faster than BIIB’s over the last 12 months.

BIIB's SMR Rating (71) in the Biotechnology industry is in the same range as SNY (75) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to SNY’s over the last 12 months.

SNY's Price Growth Rating (57) in the Pharmaceuticals Major industry is in the same range as BIIB (61) in the Biotechnology industry. This means that SNY’s stock grew similarly to BIIB’s over the last 12 months.

SNY's P/E Growth Rating (89) in the Pharmaceuticals Major industry is in the same range as BIIB (96) in the Biotechnology industry. This means that SNY’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBSNY
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
47%
Bearish Trend 2 days ago
39%
Momentum
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
55%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
47%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
53%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 2 days ago
49%
Advances
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 3 days ago
51%
Declines
ODDS (%)
Bearish Trend 5 days ago
70%
Bearish Trend 5 days ago
49%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
39%
Aroon
ODDS (%)
Bullish Trend 3 days ago
57%
Bearish Trend 2 days ago
46%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FLHY24.330.03
+0.12%
Franklin High Yield Corporate ETF
PBJA29.440.02
+0.08%
PGIM S&P 500 Buffer 20 ETF - Jan
SAWG20.57N/A
N/A
AAM Sawgrass U.S. Lg Cp Qual Gr ETF
CIBR74.38-0.04
-0.05%
First Trust NASDAQ Cybersecurity ETF
PFIX60.08-0.13
-0.22%
Simplify Interest Rate Hedge ETF

SNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNY has been loosely correlated with SNYNF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then SNYNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNY
1D Price
Change %
SNY100%
-0.06%
SNYNF - SNY
61%
Loosely correlated
N/A
GSK - SNY
53%
Loosely correlated
+0.53%
NVS - SNY
49%
Loosely correlated
-0.43%
PFE - SNY
46%
Loosely correlated
-0.04%
AZN - SNY
46%
Loosely correlated
+0.93%
More